Adaptive Biotechnologies

Temozolomide (APO-TEMOZOLOMIDE) is an oral small-molecule antineoplastic agent under development by Adaptive Biotechnologies Corp for glioblastoma, currently in Phase 3 clinical trials. The drug is an established alkylating agent with a long clinical history; multiple generic and branded formulations are already approved globally across the United States, European Union, and Australia. Adaptive Biotechnologies' program (internal code GCAR-7213) is evaluating temozolomide in glioblastoma via the pivotal trial NCT03970447, with the most recent milestone dated 15 May 2026. The compound is administered orally and belongs to the antineoplastic and immunomodulating agents therapeutic class (ATC L01). While the mechanism of action and specific target for this program are not yet disclosed, temozolomide is a well-characterized DNA-alkylating agent with decades of clinical use. Regulatory approval for temozolomide formulations already exists in major markets, with multiple manufacturers holding marketing authorizations. The Phase 3 program represents ongoing clinical validation in glioblastoma, a high-mortality indication with significant unmet medical need.

Glioblastoma remains one of the most aggressive and treatment-resistant malignancies, with median overall survival historically below 15 months despite standard-of-care multimodal therapy. The disease represents a substantial unmet medical need, particularly for patients with recurrent or refractory disease and those ineligible for aggressive surgical or radiation interventions. Temozolomide has been a cornerstone of glioblastoma management for over two decades, but resistance and tolerability challenges persist. Adaptive Biotechnologies' Phase 3 program signals continued clinical interest in optimizing temozolomide-based approaches or potentially repositioning the agent in specific patient populations or disease stages.

From a commercial perspective, glioblastoma represents a high-value oncology indication despite its relatively limited patient population, as therapies addressing this indication command premium pricing and strong market adoption. The competitive landscape includes multiple approved antineoplastic agents (Imbruvica, Afinitor, Kyprolis, Vyxeos Liposomal, and others), though few are specifically indicated for glioblastoma. Temozolomide's established safety and efficacy profile, combined with oral bioavailability and decades of clinical experience, position it favorably in discussions of standard-of-care maintenance or adjuvant therapy. Success in the Phase 3 trial could support label expansion, combination therapy claims, or new formulation advantages, potentially extending market relevance in an increasingly competitive neuro-oncology space.

Drug Class: Antineoplastic and immunomodulating agent (ATC L01)

Modality: Small molecule

Route of Administration: Oral

Mechanism of Action: Not yet disclosed for this program; however, temozolomide is a well-established alkylating agent that methylates DNA at the N-7 position of guanine, leading to DNA strand breaks and apoptosis in rapidly dividing cells.

Target: Not yet disclosed for this program.

Related Therapies: Temozolomide is part of the broader alkylating agent class and is often used in combination with radiation therapy and other chemotherapeutic agents in glioblastoma management. Other approved antineoplastic agents in the competitive landscape include tyrosine kinase inhibitors (Inlyta), mTOR inhibitors (Afinitor), proteasome inhibitors (Kyprolis), and liposomal chemotherapy formulations (Vyxeos Liposomal).

First Approval: Temozolomide formulations were first approved in Australia on 1 February 2000 and in the European Union on 2 May 2025 (among the listed authorisation dates). Multiple generic and branded versions are now approved across the US, EU, and Australia.

Patent Status: Not yet disclosed.

United States (FDA): Temozolomide is approved via multiple Abbreviated New Drug Applications (ANDAs) and one New Drug Application (NDA). Approved sponsors include Accord Healthcare, Amneal Pharmaceuticals, ANI Pharmaceuticals, Apotex, Chartwell, Chemi SPA, Deva Holding, Eirgen, Extrovis, Heritage, Hetero Labs, Merck Sharp & Dohme, Nivagen Pharmaceuticals, Rising, Sun Pharma, Watson Labs/Teva, and Zydus Pharmaceuticals. Application numbers span ANDA078879 through ANDA213328 and NDA021029, NDA022277.

European Union (EMA): Temozolomide is approved with eight EMA product numbers (EMEA/H/C/000229 through EMEA/H/C/006169). Marketing authorization holders include Accord Healthcare, Hexal AG, Merck Sharp & Dohme, Orphelia Pharma, Sandoz, Sun Pharmaceutical, Teva, and medac. Authorisation dates recorded include 2 May 2025, 6 November 2025, and 10 July 2025.

Australia (TGA): Temozolomide is approved under the brand APO-TEMOZOLOMIDE with ten PBS codes (10062N, 2438H, 8378Y, 8379B, 8380C, 8381D, 8819E, 8820F, 8821G, 9361Q). Sponsors include Alphapharm Pty Ltd, Apotex Pty Ltd, Juno Pharmaceuticals Pty Ltd, and Merck Sharp & Dohme (Australia) Pty Ltd. First listed dates range from 1 February 2000 to 1 January 2009.

China (NMPA): Temozolomide is in clinical trials in China; NCT05457829 is registered for a clinical trial in this region.

Japan (PMDA): Regulatory status not yet disclosed.

Strategic Implications: Adaptive Biotechnologies' Phase 3 program in glioblastoma with temozolomide suggests a focused strategy in high-need oncology indications. The company's decision to advance an established agent in a well-characterized indication may reflect either optimization of formulation, dosing, or patient selection, or evaluation in a specific glioblastoma subpopulation or disease stage not yet disclosed.

Competitive Implications: Temozolomide's established market presence and generic availability mean that any new indication or formulation advantage must demonstrate clear clinical or commercial differentiation. The Phase 3 trial outcome will be critical in determining whether Adaptive's program can support label expansion, combination therapy claims, or market share gains versus existing temozolomide products and emerging targeted/immunotherapies in neuro-oncology.

Future Catalysts: The next major catalyst is completion and readout of the Phase 3 trial (NCT03970447), expected to occur after the 15 May 2026 milestone. Positive efficacy or safety data could support regulatory submissions in the US, EU, and other markets. Regulatory approval or label expansion would represent a significant milestone, though timing and specific endpoints remain undisclosed.

Expected Milestones: Phase 3 trial completion and data readout; regulatory submissions (FDA, EMA, other agencies); potential approval or label expansion; commercial launch or market expansion.